[HTML] sciencedirect.com

[HTML][HTML] Oral lipid nanocomplex of BRD4 PROteolysis TArgeting chimera and vemurafenib for drug-resistant malignant melanoma

A Saraswat, R Vartak, R Hegazy, Y Fu, TJR Rao… - Biomedicine & …, 2023 - Elsevier
BRAF inhibitors (BRAFi) like vemurafenib (VEM) provide initial regression in mutated
melanoma but rapidly develop resistance. Molecular pathways responsible for development …
被引用次数：5 相关文章

Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma

A Saraswat, R Vartak, R Hegazy, Y Fu… - Biomedicine & … - pubmed.ncbi.nlm.nih.gov
BRAF inhibitors (BRAFi) like vemurafenib (VEM) provide initial regression in mutated
melanoma but rapidly develop resistance. Molecular pathways responsible for development …

Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma.

A Saraswat, R Vartak, R Hegazy, Y Fu… - Biomedicine & …, 2023 - europepmc.org
BRAF inhibitors (BRAFi) like vemurafenib (VEM) provide initial regression in mutated
melanoma but rapidly develop resistance. Molecular pathways responsible for development …